Hanmi’s Rolvedon posts sales of KRW 20.6 billion in Q2
By Son, Hyung-Min | translator Kang, Shin-Kook
24.08.13 06:00:53
가나다라
0
4.1% increase from Q1...Cumulative sales in the U.S. market reach KRW 130 billion
Same-day clinical patient enrollment complete... aims to release initial data later this year
Sales of Rolvedon (Korean brand name: Rolontis), a new anti-cancer drug developed by Hanmi Pharmaceutical, are showing signs of recovery in the U.S. market. Hanmi Pharmaceutical's U.S. partner Assertio plans to increase Rolvedon’s market share through new clinical trials that could ensure the drug’s advantage in convenience of administration.
According to Assertio on the 12th, Rolvedon generated USD 15.1 million in U.S. market sales in Q2 this year, down 28.1% YoY, but up 4.1% from the previous quarter.
Rolvedon is a neutropenia treatment developed by Hanmi Pharmaceutical and was approved as the 33rd homegrown new drug in Korea in March 2021. Hanmi Pharmaceutical and its U.S. partner Spect
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)